compared to its average ratio and a 36-month beta value of 0.52. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Viking Therapeutics Inc. (VKTX) is $33.80, which is $20.13 above the current market price. The public float for VKTX is 93.71M, and currently, short sellers hold a 13.78% ratio of that float. The average trading volume of VKTX on September 18, 2023 was 2.35M shares.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
VKTX) stock’s latest price update
The stock of Viking Therapeutics Inc. (NASDAQ: VKTX) has decreased by -7.45 when compared to last closing price of 14.77. Despite this, the company has experienced a -13.37% fall in its stock price over the last five trading sessions. PRNewsWire reported 2023-09-07 that SAN DIEGO, Sept. 7, 2023 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences.
VKTX’s Market Performance
Viking Therapeutics Inc. (VKTX) has seen a -13.37% fall in stock performance for the week, with a -3.32% decline in the past month and a -35.15% plunge in the past quarter. The volatility ratio for the week is 4.70%, and the volatility levels for the past 30 days are at 4.73% for VKTX. The simple moving average for the past 20 days is -5.45% for VKTX’s stock, with a -3.89% simple moving average for the past 200 days.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with ROTH MKM repeating the rating for VKTX by listing it as a “Buy.” The predicted price for VKTX in the upcoming period, according to ROTH MKM is $32 based on the research report published on May 31, 2023 of the current year 2023.
VKTX Trading at -6.35% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.85% of loss for the given period.
Volatility was left at 4.73%, however, over the last 30 days, the volatility rate increased by 4.70%, as shares sank -4.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.00% lower at present.
During the last 5 trading sessions, VKTX fell by -15.21%, which changed the moving average for the period of 200-days by +239.59% in comparison to the 20-day moving average, which settled at $14.43. In addition, Viking Therapeutics Inc. saw 45.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Rowland Charles A Jr, who sale 40,000 shares at the price of $25.00 back on May 16. After this action, Rowland Charles A Jr now owns 30,000 shares of Viking Therapeutics Inc., valued at $1,000,000 using the latest closing price.
MACARTNEY LAWSON, the Director of Viking Therapeutics Inc., sale 16,000 shares at $24.00 during a trade that took place back on May 16, which means that MACARTNEY LAWSON is holding 47,965 shares at $384,000 based on the most recent closing price.
Stock Fundamentals for VKTX
The total capital return value is set at -40.34, while invested capital returns managed to touch -39.53. Equity return is now at value -36.30, with -33.40 for asset returns.
Based on Viking Therapeutics Inc. (VKTX), the company’s capital structure generated 1.08 points at debt to equity in total, while total debt to capital is 1.06. Total debt to assets is 0.93, with long-term debt to equity ratio resting at 0.87. Finally, the long-term debt to capital ratio is 0.86.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.
Conclusion
To put it simply, Viking Therapeutics Inc. (VKTX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
